Global Toxoid Vaccines Market is valued at USD 4.97 Billion in 2021 and expected to reach USD 6.81 Billion by 2028 with a CAGR of 4.6% over the forecast period.
Global Toxoid Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of tetanus and diphtheria, rising number of technological advancements, and growing supportive initiatives taken by the government are some of the major factors anticipated to drive the growth of Global Toxoid Vaccine Market.
Get Sample Report: https://brandessenceresearch.com/requestSample/PostId/1902
Scope of Global Toxoid Vaccines Market:-
Toxoid vaccines are used to induce an immune response against diseases caused by specific bacteria by using toxoids as antigens. The immunity against specific the body is able to form an immune response to the original toxin. This vaccine provides protection against tetanus in adults and children seven years or older. By utilizing toxoids, the body can shape an immune reaction to the first poison, yet since the toxoid is a debilitating type of toxoid, it can’t prompt any toxicity or toxin-induced illness. Contrasted with different vaccines, toxoid vaccines are steadier and less defenseless to harm brought about by temperature, stickiness, or light. Generally, toxoid vaccines are given as a feature of a course of various dosages all through youth and adulthood for greatest security, and booster shots can be given in the event that are traveling to a high-hazard country for instance. Toxoid vaccines are more stable than compared to other vaccines. Toxoid vaccines are extremely effective and safe vaccines for tetanus and diphtheria. Vaccinations against these diseases are given as part of routine childhood vaccinations and have resulted in over 90-95% drop in cases and deaths worldwide since their introduction. A successful toxoid vaccine created in 1938 and used to prevent tetanus in the military during World War II.
The Covid-19 pandemic has also impacted the growth of global toxoid vaccines market. Unplanned disruption in all areas of life, including the delivery of health services like vaccinations were affected during pandemic. Vaccination drive for toxoid vaccines slowed down due to lockdown and focus of healthcare industry has shifted on Covid-19. Thus, the toxoid vaccines market negatively impacted during COVID -19 pandemic.
Global toxoid vaccines Segmentation:
The global toxoid vaccines market is segmented into on the basis of type, indication, distribution channel, application, end-user and region & country level. On the basis of type, the global toxoid vaccines market is segmented into monovalent tetanus toxoid (TT), tetanus-diphtheria (Td), diphtheria, tetanus, Pertussis (DTaP) and others. On the basis of indication, the market is classified into Tetanus, Pertussis, Diphtheria and others. On the basis of distribution channel, the global toxoid vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of application, the market is segmented into neonatal and adult. On the basis of end-user, the global toxoid vaccines market is classified into hospitals, specialty centers and others.
- Monovalent Tetanus Toxoid (TT)
- Tetanus-diphtheria (Td)
- Diphtheria, Tetanus
- Pertussis (DTaP)
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Centers
Key Players of Global Toxoid Vaccines Market-
Some of the key players for global toxoid vaccines market are
- Serum Institute
- Valeant Pharmaceuticals
- GlaxoSmithKline Plc
- Astellas Pharma Inc
- Merck & Co. Inc
- Pfizer Inc
- Bharat Biotech
- Emergent BioSolutions Inc
News-Cipla Launched Affordable Tetanus Vaccine to Prevent Tetanus Deaths
On December 8th, 2020; A new tetanus toxoid vaccine announced by Cipla in partnership with the Serum Institute of India. The vaccine can be used for prevention of tetanus in infants, children and adults. It will be distributed to hospitals and clinics in 5ml vials, which may deliver 10 doses each and last for up to 28 days once opened.
FDA Approved Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
On January 14th, 2019; The U.S. Food and Drug Administration approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
Increasing Prevalence of Tetanus and Diphtheria, Rising Clinical Trials of Toxoid Vaccines and Growing Supportive Initiatives Taken by the Government are Driving the Market Growth
North America is expected to dominate the global toxoid vaccines market due to the increasing cases of tetanus and diphtheria, rising adoption of vaccines and growing research & development activities in this region. For instance; according to the Centers for Disease Control and Prevention (CDC); about 33 tetanus cases and two deaths were reported every year in the United States. In addition to that, five doses of DTaPas well asdiphtheria and Pertussis was made mandatory by the U.S. childhood immunization schedule as well as diphtheria and Pertussis, which is boosting the market growth. Furthermore, growing awareness and research and development in vaccines and rising focus to control the incidence and highly developed infrastructure augmenting the growth of the global toxoid vaccines market in this region.
Asia Pacific is the second-largest market for the global toxoid vaccines market due to the increasing population, supportive government initiatives for controlling disease and rising awareness about vaccines. For instance; according to ministry of health and family Welfare; in 2016 diphtheria outbreak in Kerala, nearly 79%cases occurred in 10 years age group. In addition to that, on August 15th, 2018, Tetanus Toxoid (TT) vaccine was replaced by a Tetanus and Diphtheria (Td) combination vaccine as guided by World Health Organization (WHO).
Get Full Report: https://brandessenceresearch.com/vaccines/toxoid-vaccines-market-size
The Global Surgical Instrument Tracking Systems Market in terms of revenue was worth of USD 193.8 Million in 2021 and is Projected to reach USD 513.1 Million by 2028, growing at a CAGR of 14.92% from 2021 to 2027.
Animal Vaccine Market was worth of USD 11.13 billion in 2021 and it is expected to reach 20.48 billion by the end of 2028 with the CAGR of 9.1% during Forecast Period.
Hemophilia Gene Therapy Market is valued at USD 331.4 Million in 2021 and expected to reach USD 4092.6 Million by 2028 with a CAGR of 43.2% over the forecast period.
Global Bioinformatics Market in terms of revenue was worth of USD 10.82 Billion in 2021 and expected to reach USD 24.07 Billion by 2028, growing at a CAGR of 12.1% from 2021 to 2028.
Colorectal Cancer Market is valued at USD 11.83 Billion in 2021 and is expected to reach USD 16.21 Billion by 2028 with a CAGR of 5.40% over the forecast period.
Global Medical Tricorder Market is valued at USD 3425.4 Million in 2021 and is expected to reach USD 5411.2 Million by 2028 with a CAGR of 6.75% over the forecast period.
Global Healthcare CRM Market is valued at USD 12.53 Billion in 2021 and is expected to reach USD 31.54 Billion by 2028 with a CAGR of 14.1% over the forecast period.
The Global Metaverse in Healthcare Market is valued at USD 5056.4 Million in 2021 and is expected to reach USD 7453.6 Million by 2028 with a CAGR of 33.7% over the forecast period.
Global Demand For Advanced Wound Care Market, in terms of revenue, was estimated to be USD 9.01 billion in 2018 and is expected to reach USD 13.27 billion in 2025, growing at a CAGR of 5.85% from 2019 to 2025.
According to Brandessence Market Research latest research study says Global demand for biophotonics market size in terms of revenue, was worth of USD 53.28 Billion in 2020. The biophotonics market is likely to reach USD 109.23 Billion by 2027 end, growing at a robust 10.8% CAGR.
The Global Sterility Testing Market in terms of revenue was worth of USD 1036.13 Million in 2021 and expected to reach USD 2193.8 Million by 2028, growing at a CAGR of 12.6% from 2021 to 2028.
i-Factor: Live Market intelligence platform
I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister
Brandessence Market Research & Consulting Pvt ltd.
Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Mr. Vishal Sawant
Corporate Sales: +44-2038074155
Asia Office: +917447409162